However, in the same study, the expression of CBX3 remained unaltered in EGFR mutant NSCLC cell lines treated with the EGFR inhibitor gefitinib [94], suggesting that the downstream signaling of EGFR may not influence the expression of CBX3 [91]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.